Clinical and experimental advances in treatment of visceral leishmaniasis

Affiliations

Review

H W Murray. Antimicrob Agents Chemother. 2001 Aug.

. 2001 Aug;45(8):2185-97.

doi: 10.1128/AAC.45.8.2185-2197.2001.

¹ Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA. hwmurray@med.cornell.edu

No abstract available

References

1. Ahuja S S, Reddick R L, Sato N, Montalbo E, Kostecki V, Zhao W, Dolan M J, Melby P C, Ahuja S K. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol. 1999;163:3890–3897. - PubMed
1. Al-Abdely H M, Graybill J R, Bocanegra R, Najvar L, Montalbo E, Regen S L, Melby P C. Efficacies of KY62 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous leishmaniasis and visceral leishmaniasis. Antimicrob Agents Chemother. 1998;42:2542–2548. - PMC - PubMed
1. Al-Abdely H A, Graybill J R, Loebenberg D, Melby P C. Efficacy of the triazole SCH 56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniasis. Antimicrob Agents Chemother. 1999;43:2910–2914. - PMC - PubMed
1. Alexander J, Carter K C, Al-Fasi N, Satoskar A, Brombacher F. Endogenous IL-4 is necessary for effective drug therapy against visceral leishmaniasis. Eur J Immunol. 2000;30:2935–2943. - PubMed
1. Almeida R, D'Oliveira A, Machado P, Barcellar O, Ko A I, de Jesus A R, Mobashery N, Santis J B, Carvalho E M. Randomized, double-blind study of stibogluconate plus human granulocyte macrophage colony-stimulating factor versus stibogluconate alone in the treatment of cutaneous leishmaniasis. J Infect Dis. 1999;180:1735–1737. - PubMed